GeoVax Labs, Inc. (NASDAQ:GOVX) Sees Large Increase in Short Interest

GeoVax Labs, Inc. (NASDAQ:GOVX) saw a significant growth in short interest in August. As of August 31st, there was short interest totalling 794,700 shares, a growth of 17.1% from the August 15th total of 678,900 shares. Based on an average trading volume of 396,700 shares, the short-interest ratio is presently 2.0 days.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and set a $8.00 target price on shares of GeoVax Labs in a report on Thursday, August 31st.

Hedge Funds Weigh In On GeoVax Labs

Several large investors have recently modified their holdings of GOVX. Virtu Financial LLC bought a new position in shares of GeoVax Labs in the first quarter valued at about $57,000. Renaissance Technologies LLC bought a new position in GeoVax Labs during the second quarter worth about $333,000. Millennium Management LLC bought a new position in GeoVax Labs during the second quarter worth about $27,000. BlackRock Inc. increased its position in GeoVax Labs by 104,042.1% during the third quarter. BlackRock Inc. now owns 413,444 shares of the company’s stock worth $451,000 after acquiring an additional 413,047 shares during the period. Finally, Vanguard Group Inc. increased its position in GeoVax Labs by 112.5% during the third quarter. Vanguard Group Inc. now owns 549,966 shares of the company’s stock worth $600,000 after acquiring an additional 291,200 shares during the period. 6.09% of the stock is owned by institutional investors.

GeoVax Labs Stock Performance

Shares of GOVX stock opened at $0.54 on Tuesday. The company has a fifty day moving average price of $0.57 and a two-hundred day moving average price of $0.62. GeoVax Labs has a one year low of $0.51 and a one year high of $1.39.

GeoVax Labs (NASDAQ:GOVX) last issued its quarterly earnings data on Wednesday, August 9th. The company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.06). On average, research analysts expect that GeoVax Labs will post -0.64 EPS for the current year.

About GeoVax Labs

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.